Related Experiment Video

Updated: Dec 12, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K

Pharmacogenomics, Pharmacokinetics and Circulating Proteins as Biomarkers for Bevacizumab Treatment Optimization in

Apostolos Papachristos1, Gregory B Sivolapenko1

  • 1Laboratory of Pharmacokinetics, Department of Pharmacy, School of Health Sciences, University of Patras, 26504 Patras, Greece.

Journal of Personalized Medicine
|August 8, 2020
PubMed

Insights

Bevacizumab, an anti-angiogenesis cancer drug, needs better predictive factors for treatment success. This review explores biomarkers, pharmacogenomics, and drug monitoring to optimize its use in precision medicine.

Area of Science:

  • Oncology
  • Translational Research
  • Pharmacology

Background:

  • Bevacizumab is a monoclonal antibody targeting VEGF-A, crucial for inhibiting tumor angiogenesis.
  • Approved for various cancers like mCRC, ovarian, and lung cancer, it's a widely used oncology agent.
  • A significant gap exists in validated predictive factors for bevacizumab treatment outcomes.

Purpose of the Study:

  • To review and present literature on optimizing bevacizumab use through predictive strategies.
  • To explore the clinical application of biomarkers, pharmacogenomics (PG), and therapeutic drug monitoring (TDM).
  • To advance precision medicine approaches for bevacizumab therapy.

Main Methods:

  • Comprehensive literature review of clinical studies.
  • Analysis of biomarkers, pharmacogenomics, and therapeutic drug monitoring data.
  • Focus on translational research in anti-VEGF therapy.

Main Results:

  • Identified various biomarkers and PG factors showing potential in predicting bevacizumab response.
  • Highlighted the role of TDM in tailoring bevacizumab dosage for improved efficacy.
  • Demonstrated the growing body of evidence supporting personalized bevacizumab treatment strategies.

Conclusions:

  • Biomarkers, PG, and TDM are essential tools for optimizing bevacizumab therapy.
  • These approaches are key to advancing precision medicine in oncology.
  • Further validation is needed to fully integrate these predictive factors into clinical practice.
Keywords:
VEGF-Aanti-angiogenetic therapybevacizumabbiomarkerspharmacogenomicspharmacokineticsprecision medicinetherapeutic drug monitoring

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.8K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.0K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
118
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
223
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
107
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
144